Author: Dauby, Nicolas; Van Praet, Serge; Vanhomwegen, Charlotte; Veliziotis, Ioannis; Konopnicki, Deborah; Roman, Alain
Title: Tolerability of Favipiravir therapy in critically-ill patients with COVID-19: a report of 4 cases. Cord-id: w0rpk22o Document date: 2020_9_4
ID: w0rpk22o
Snippet: Favipiravir (FVP) is an RNA polymerase inhibitor with broad anti-viral activity1 . FVP is a pro-drug which is ribosylated and phosphorylated intracellularly to form the active metabolite and has a short half-life (2-5.5 hours) after oral administration2 . This article is protected by copyright. All rights reserved.
Document: Favipiravir (FVP) is an RNA polymerase inhibitor with broad anti-viral activity1 . FVP is a pro-drug which is ribosylated and phosphorylated intracellularly to form the active metabolite and has a short half-life (2-5.5 hours) after oral administration2 . This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date